Global Model Identifies Stage II Colon Cancer Patients Who Need Adjuvant Chemotherapy

A novel recurrence risk model (rpv) effectively identifies stage II colon cancer patients who will benefit from adjuvant chemotherapy (AC). Analysis of cohorts from the U.S., Japan, Denmark, and Jordan reveals that high-risk patients achieving higher five-year recurrence-free survival (RFS) rates with AC—76.2% in cohort 1 and 65.6% in cohort 2—compared to non-recipients. This model provides critical insights for tailoring treatment plans in diverse populations, reinforcing AC’s role for select high-risk patients.